Recently, researchers reported that BCL6B played a pivotal role as a potential tumour suppressor in GC, and the detection of methylation of the BCL6B DNA promoter might be deemed an independent biomarker for the prognosis of GC [7]. This evidence concerns the gene BCL6B and gastric cancer.